Clinical trial
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype
NCT05207709
Study timeline
Study start (actual)2022-03-28Date precision: day
Registry last updated2026-06-25
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Metastatic Breast Cancerunresolved
Interventions
Sponsors & collaborators
SOLTI Breast Cancer Research Grouplead sponsor
Novartiscollaborator
Alliance Foundation Trials, LLC.collaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05207709 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.